NDC 50242-087

KADCYLA

Ado-trastuzumab Emtansine

KADCYLA is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Ado-trastuzumab Emtansine.

• Product ID: 50242-087_025ce8f1-7c1e-4926-9657-daaa1e213dff
• NDC: 50242-087
• Product Type: Human Prescription Drug
• Proprietary Name: KADCYLA
• Generic Name: Ado-trastuzumab Emtansine
• Dosage Form: Injection, Powder, Lyophilized, For Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2013-02-22
• Marketing Category: BLA / BLA
• Application Number: BLA125427
• Labeler Name: Genentech, Inc.
• Substance Name: ADO-TRASTUZUMAB EMTANSINE
• Active Ingredient Strength: 20 mg/mL
• NDC Exclude Flag: N
• Listing Certified Through: 2020-12-31

Packaging

NDC 50242-087-01

1 VIAL, SINGLE-USE in 1 CARTON (50242-087-01) > 8 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 2013-02-22
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 50242-087-01 [50242008701]

KADCYLA INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

• Marketing Category: BLA
• Application Number: BLA125427
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2013-02-22

Drug Details

Active Ingredients

Ingredient	Strength
ADO-TRASTUZUMAB EMTANSINE	20 mg/mL

OpenFDA Data

• SPL SET ID: 23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
• Manufacturer:
  • Genentech, Inc.
• UNII:
  • SE2KH7T06F
• RxNorm Concept Unique ID - RxCUI:
  • 1658084
  • 1658087
  • 1658091
  • 1658089

NDC Crossover Matching brand name "KADCYLA" or generic name "Ado-trastuzumab Emtansine"

NDC	Brand Name	Generic Name
50242-087	KADCYLA	ADO-TRASTUZUMAB EMTANSINE
50242-088	KADCYLA	ADO-TRASTUZUMAB EMTANSINE